What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis?

References

• Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016. doi:10.1016/S0140-6736(16)30173-8. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Emery P. Early arthritis. In: Smolen JS, Lipsky PE, editors. Targeted therapies in rheumatology. London: Martin Dunitz; 2003. p. 509–513.
   Google Scholar
• Nell VP, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2004;43:906–914.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964–975.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
   PubMed Web of Science ®Google Scholar
• Kuriya BL, Arkema EV, Bykerk VP, et al. Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission. Ann Rheum Dis. 2010;69:1298–1304.
   PubMed Web of Science ®Google Scholar
• Van Den Broek M, Lems WF, Allaart CF. Do we need guidelines to stop as well as to start biological therapies for rheumatoid arthritis? Clin Exp Rheumatol. 2012;30(Suppl. 73):SS21–S6.
   Google Scholar
• Felson D. Defining remission in rheumatoid arthritis. Ann Rheum Dis. 2012;71(Suppl 2):i86–i88.
   PubMed Web of Science ®Google Scholar
• Schett G, Emery P, Tanaka Y, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis. 2016 Jun 3; 75:1428–1437.
   PubMed Web of Science ®Google Scholar
• O’Mahony R, Richards A, Deighton C, et al. Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2010;69:1823–1826.
   PubMed Web of Science ®Google Scholar
• Gøtzsche PC, Hansen M, Stoltenberg M, et al. Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. Scand J Rheumatol. 1996;25:194–199.
   PubMed Web of Science ®Google Scholar
• Ahern MJ, Hall ND, Case K, et al. D-Penicillamine withdrawal in rheumatoid arthritis. Ann Rheum Dis. 1984;43:213–217.
   PubMed Web of Science ®Google Scholar
• De Silva M, Hazleman BL. Long-term azathioprine in rheumatoid arthritis: a double blind study. Ann Rheum Dis. 1981;40:560–563.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Rynes RI, Bartholomew LE. Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy. Double-blind study. Am J Med. 1987;82:781–786.
   PubMed Web of Science ®Google Scholar
• Ten Wolde S, Breedveld FC, Hermans J, et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet. 1996;347:347–352.
   PubMed Web of Science ®Google Scholar
• Van Der Leeden H, Dijkmans BA, Hermans J, et al. A double-blind study on the effect of discontinuation of gold therapy in patients with rheumatoid arthritis. Clin Rheumatol. 1986;5:56–61.
   PubMed Web of Science ®Google Scholar
• Bacon PA, Myles AB, Beardwell CG, et al. Corticosteroid withdrawal in rheumatoid arthritis. Lancet. 1966;2:935–937.
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Cohen SB, Moreland LW, et al.; iRAMT Study Group. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the infliximab rheumatoid arthritis methotrexate tapering (iRAMT) trial. Curr Med Res Opin. 2005;21:1181–1190.
   PubMed Web of Science ®Google Scholar
• Tishler M, Caspi D, Yaron M. Methotrexate treatment of rheumatoid arthritis: is a fortnightly maintenance schedule enough? Ann Rheum Dis. 1992;51:1330–1331.
   PubMed Web of Science ®Google Scholar
• Van Der Woude D1, Young A, Jayakumar K, et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum. 2009;60:2262–2271.
   PubMed Web of Science ®Google Scholar
• Tiippana-Kinnunen T, Paimela L, Kautiainen H, et al. Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up. Scand J Rheumatol. 2010;39:12–18.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Takeuchi T, Mimori T, et al.; RRR study investigators. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 2010;69:1286–1291.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis. 2015;74:389–395.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Emery P, Ferraccioli GF, et al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Ann Rheum Dis. 2015;74:843–850.
   PubMed Web of Science ®Google Scholar
• Nishimoto N1, Amano K, Hirabayashi Y, et al. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol. 2014;24:17–25.
   PubMed Web of Science ®Google Scholar
• Huizinga TW, Conaghan PG, Martin-Mola E, et al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis. 2015;74(1):35–43.
   PubMed Web of Science ®Google Scholar
• Van Den Broek M, Klarenbeek NB, Dirven L, et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis. 2011;70:1389–1394.
   PubMed Web of Science ®Google Scholar
• Nam JL, Villeneuve E, Hensor EMA, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis. 2014;73:75–85.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet. 2014;383:321–332.
   PubMed Web of Science ®Google Scholar
• Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis. 2013;72:844–850.
   PubMed Web of Science ®Google Scholar
• Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015;74:19–26.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Kishimoto M, Radner H, et al. Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry. Rheumatology (Oxford). 2016;55:286–290.
   PubMed Web of Science ®Google Scholar
• Deighton C, O’Mahony R, Tosh J, et al.; Guideline Development Group. Management of rheumatoid arthritis: summary of NICE guidance. BMJ. 2009;338:b702.
   PubMed Web of Science ®Google Scholar
• Caporali R, Conti F, Alivernini S, et al. Italian Society for Rheumatology. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. Clin Exp Rheumatol. 2011;29(3Suppl 66):S7–14.
   PubMed Web of Science ®Google Scholar
• Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625–639.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr, et al. American College of Rheumatology. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68(1):1–25.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Pham T, Alfaiate T, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Ann Rheum Dis. 2016;75(1):59–67.
   PubMed Web of Science ®Google Scholar
• Smolen JS1, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet. 2013;381(9870):918–929.
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven RF, Østergaard M, Leirisalo-Repo M, et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis. 2016;75(1):52–58.
   PubMed Web of Science ®Google Scholar
• Raffeiner B, Botsios C, Ometto F, et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clin Exp Rheumatol. 2015;33(1):63–68.
   PubMed Web of Science ®Google Scholar
• Haschka J, Englbrecht M, Hueber AJ, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis. 2016;75(1):45–51.
   PubMed Web of Science ®Google Scholar
• Emery P, Hammoudeh M, FitzGerald O, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med. 2014;371(19):1781–1792.
   PubMed Web of Science ®Google Scholar
• Westhovens R, Robles M, Ximenes AC, et al. Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis. Ann Rheum Dis. 2015;74(3):564–568.
   PubMed Web of Science ®Google Scholar
• Rech J, Hueber AJ, Finzel S, et al. Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment. Ann Rheum Dis. 2016;75(9):1637–1644.
   Web of Science ®Google Scholar
• Naredo E, Valor L, De La Torre I, et al. Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis. Rheumatology (Oxford). 2015;54(8):1408–1414.
   PubMed Web of Science ®Google Scholar
• Alivernini S, Peluso G, Fedele AL, et al. Tapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission. Arthritis Res Ther. 2016;18:39.
   PubMed Web of Science ®Google Scholar